Nissui Pharmaceutical Co., Ltd. (E00971) Stock Price

Nissui Pharmaceutical is a healthcare company that manufactures and sells diagnostic drugs, test reagents, and testing equipment. The company supplies drugs and equipment necessary for medical testing used in healthcare facilities, playing a vital role in disease diagnosis and health management. As a member of the Nippon Suisan Group, the company develops products by leveraging technology and expertise cultivated in the fisheries business.

The company's primary customers are medical institutions and testing facilities, generating revenue by supplying diagnostic and testing products to these facilities. Transactions with its parent company, Nippon Suisan, also serve as an important revenue source, and the company has established a cooperative framework within the group. The company procures raw materials from group companies while simultaneously engaging in two-way transactions that include product and merchandise sales.

The business operates as a single segment focused on diagnostic drugs, though the product line is diverse. For diagnostic and test drugs, the company employs both in-house manufacturing and external procurement. For testing equipment, it primarily handles sales of purchased products. Additionally, the company manufactures, procures, and sells raw materials for these products in an integrated manner, ensuring stable quality control and supply systems.

Nissui Pharmaceutical has established a new three-year medium-term management plan aimed at realizing "a company with sustainable long-term growth." The company prioritizes Return on Invested Capital (ROIC) and Cash Conversion Cycle (CCC) as key management metrics, with a policy to improve profitability and efficiency through effective asset utilization. Through aggressive investment, the company seeks to create new value by nurturing existing businesses and advancing new business initiatives, while pursuing the maximization of corporate value.

A cornerstone of the company's strategic priorities is platform development across all business segments. The company is advancing multi-business operations within a unified platform through monetization of services utilizing its proprietary quality management system "Ni-QCS" and the promotion of e-commerce business. Additionally, the company is strengthening partnerships with medical device manufacturers and software makers to enhance its capabilities in system medical devices, thereby achieving differentiation.

In new market development, the company is expanding next-generation rapid susceptibility testing and microbial identification businesses to address multidrug-resistant bacteria, while also focusing on infectious disease testing services utilizing PCR testing equipment. In response to an aging society, the company is developing over-the-counter (OTC) diagnostic tests and aims to expand its business scope through growth in food analysis outsourcing services. Through these initiatives, the company is also considering entry into the home healthcare market.

At the core of technological innovation is the open innovation program "NeyeS." The company leverages insights gained from joint research with external partners and has set a target for new product commercialization within three years. Through this program, the company is accelerating new business development and technological advancement beyond traditional business boundaries, while promoting the creation of innovative products and services that will serve as the foundation for global expansion.